[Comparison of clinical outcome between allogeneic peripheral blood stem cell transplantation and bone marrow transplantation].
OBJECTIVE
To compare the clinical outcome of allogeneic peripheral blood stem cell transplantation(PBSCT) with that of bone marrow transplantation(BMT).


METHODS
Twenty-six patients received allo-BMT and 24 received allo-PBSCT in our hospital between August 1991 and September 1998. Conditioning regimens were CY 120 mg/kg plus STBI 9-10 Gy or BU 16 mg/kg or Mel 140-160 mg/m2 plus CY 120 mg/kg.


RESULTS
Twenty-three patients of PBSCT and 24 of BMT group engrafted successfully. The median follow-up duration was 352(19-745) days for the PBSCT group and 546(19-2,329) days for the BMT group. Transplant-related death was 4(16.7%) patients in the PBSCT and 7(26.9%) in BMT group (P = 0.38). Three(12.5%) patients in PBSCT and 5(19.2%) in BMT group relapsed(P = 0.27). The 2-year probabilities of disease-free survival(DFS) for PBSCT and BMT group were (67.9 +/- 11.3)% and (57.7 +/- 9.7)%, respectively(P = 0.24). aGVHD occurred in 6(25%) patients in the PBSCT and 6 (23.1%) in the BMT group (P = 0.624), while cGVHD did in 13(56.5%) and 1 (3.85%), respectively (P = 0.0002).


CONCLUSIONS
The clinical outcome of allo-PBSCT is similar to allo-BMT, except for a higher incidence of cGVHD.
Wang
M
M
Institute of Hematology, CAMS and PUMC, Tianjin 300020.
Han
M
M
Feng
S
S
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002681:China / Q000453:epidemiology; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D014184:Transplantation, Homologous